Sandu Pharmaceuticals (524703) Q3 25/26 earnings summary

Executive summary

• Unaudited standalone financial results for the quarter and nine months ended 31st December 2025 were reviewed and approved by the Board on 6th February 2026.

• Financial statements were prepared in accordance with Indian Accounting Standards (IND AS) and reviewed by statutory auditors.

Financial highlights

• Revenue from operations for Q3 FY26 was ₹1,876.09 lakhs, up from ₹1,762.11 lakhs in the previous quarter and ₹1,837.29 lakhs in Q3 FY25.

• Net profit for Q3 FY26 stood at ₹97.51 lakhs, compared to ₹52.43 lakhs in the previous quarter and ₹55.55 lakhs in Q3 FY25.

• Total comprehensive income for Q3 FY26 was ₹114.47 lakhs, up from ₹66.31 lakhs in the previous quarter and ₹73.80 lakhs in Q3 FY25.

• Earnings per share (EPS) for Q3 FY26 was ₹1.01, compared to ₹0.54 in the previous quarter and ₹0.57 in Q3 FY25.

Outlook and guidance

• Management continues to evaluate performance based on revenue and operating income in the Ayurvedic Property Medicines segment.